Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

被引：0
|
作者：
Zhang, L. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7627
引用
收藏
页数：1
相关论文
共 50 条
  • [41] SARCOPENIA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Grendarova, Petra
    Arora, Rahul
    Bebb, Gwyn
    D'Silva, Adrijana
    Robyn, Banerjee
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S87 - S87
  • [42] Genomic profiling associated with survival in stage IIIA-B non-small cell lung cancer (NSCLC) patients treated with radiotherapy
    Bi Nan
    Wang Luhua
    Zhang Li
    Yang Ming
    Chen Xiabing
    Lin Dongxin
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S499 - S500
  • [43] Combination of Gemcitabine (Gem) and Carboplatin (Carbo) as first line treatment in non-small cell lung cancer (NSCLC)
    Carrato, A
    Alberola, V
    Massuti, B
    Galan, A
    Sanchez, JJ
    Garcia-Gomez, J
    Diaz-Fernandez, N
    Meana, A
    Rodriguez-Lescure, A
    Gonzalvez, ML
    ANNALS OF ONCOLOGY, 1998, 9 : 89 - 90
  • [44] Gemcitabine (Gem) and paclitaxel (Tax); pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer (NSCLC)
    Kroep, JR
    Voorn, DA
    Giaccone, G
    Postmus, PE
    van Moorsel, CJA
    Beijnen, JH
    Rosing, H
    Loves, WJP
    Smit, EF
    Gall, H
    van Groeningen, CJ
    Pinedo, HM
    Peters, GJ
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [45] Genetic Polymorphisms Associated With Toxicity Are Associated With Overall Survival Following Curative Radiation for Non-Small Cell Lung Cancer
    Barrett, K.
    Xu, J.
    Kim, S.
    Boyd, K.
    Cheng, D.
    Chen, Z.
    Bezjak, A.
    Sun, A.
    Cho, J.
    Brade, A.
    Leighl, N.
    Shepherd, F.
    Xu, W.
    Liu, G.
    Hope, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S811 - S811
  • [46] Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab
    Goldberg, Sarah B.
    Gettinger, Scott N.
    Mahajan, Amit
    Herbst, Roy S.
    Chiang, Anne C.
    Lilenbaum, Rogerio
    Jilaveanu, Lucia
    Rowen, Elin
    Gerrish, Heather
    Komlo, Annette
    Wei, Wei
    Chiang, Veronica
    Kluger, Harriet M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Association Between Baseline Tumor Diameters and Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gerber, D. E.
    Dahlberg, S. E.
    Sandler, A. B.
    Perry, M. C.
    Schiller, J. H.
    Brahmer, J. R.
    Johnson, D. H.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S217 - S218
  • [48] Gemcitabine/carboplatin in advanced non-small cell lung cancer
    Zatloukal, P
    Petruzelka, L
    LUNG CANCER, 2002, 38 : S33 - S36
  • [49] Gemcitabine and vinorelbine in advanced non-small cell lung cancer
    Vazquez, F
    Cueva, JF
    Baron, FJ
    Candamio, S
    Calvo, M
    Irigoyen, A
    Huidobro, C
    Lopez, R
    ANNALS OF ONCOLOGY, 1998, 9 : 103 - 103
  • [50] Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)
    Onishchenko, Dmitry
    Dunyak, James
    Masson, Eric
    Helmlinger, Gabriel
    Peskov, Kirill
    Tomkinson, Helen
    Stanski, Donald
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S138 - S138
12345